PredOmix, CORE Diagnostics partner to launch OncoVeryx-F for early cancer detection for women

146

PredOmix Technologies Pvt. Ltd, a health technology pioneer and innovation-driven company, announced its collaboration with CORE Diagnostics, to launch and market OncoVeryx-F, a cutting-edge multi-cancer early detection (MCED) test specifically designed for cancer screening in high-risk and asymptomatic women.

Detecting cancers at an early stage not only allows for prompt interventions but it provides patients with better treatment options, enhancing the chances of successful outcomes and improved quality of life. Early-stage cancers are often localized, making them more amenable to curative treatments such as surgery, radiation therapy, and targeted therapies.

OncoVeryx-F, a proprietary test developed by PredOmix, is set to transform early-stage cancer detection and improve treatment outcomes. The test’s ability to identify cancer even at Stage 1 and 2 increases the likelihood of successful treatment, providing patients a better chance of recovery. With an impressive accuracy rate of 98%, OncoVeryx-F can screen for the presence or absence of cancer and accurately identify the Tissue of Origin (TOO) in a single test.

Moreover, the test offers a major advantage as it can be performed using a simple blood sample, providing a convenient and non-invasive screening method for individuals. This breakthrough technology offers a comprehensive screening solution for four cancers, including breast, endometrial, cervical, and ovarian cancer.

PredOmix’s Dr. Kanury Rao says, early cancer detection is what saves lives. OncoVeryx-F is a simple blood test that looks for cancer metabolic signatures in the bloodstream” Dr. Rao further adds saying, “This test is very significant for women. We have developed this test for early detection, so we can diagnose cancer earlier and so treatment can begin earlier and avoid some of the long-term problems and help women live longer. Together with Core Diagnostics, we aim to reduce the number of advanced cancers in the country”.

“We are thrilled to collaborate with PredOmix to bring OncoVeryx-F to the market,” says Dinesh Chauhan, CEO of CORE Diagnostics.

“This ground-breaking multi-cancer detection test represents a significant advancement in early-stage cancer diagnosis. By combining the expertise of PredOmix with our commitment to improving patient outcomes, we aim to make a tangible difference in the lives of women at high risk for cancer,” he adds.

CORE Diagnostics is a rapidly expanding and leading clinical diagnostic laboratory in India, renowned for its specialization and expertise in the field of oncology. With a focus on delivering high-end diagnostic and genetic services, CORE Diagnostics is actively working to expand its presence beyond India and establish itself in countries across Asia, the Middle East, and Africa. CORE Diagnostics established its first lab in 2012 at Gurugram, which is NABL and CAP accredited.

Founded in 2018, PredOmix Technologies Pvt. Ltd expertise lies in integrating multi-dimensional approaches and harnessing the power of deep learning to develop cutting-edge technologies in preventive healthcare and early-stage disease diagnosis.